Please login to the form below

Not currently logged in
Email:
Password:

Bayer's Martin Hesse moves to Daiichi Sankyo Europe

Will succeed Max Schöner, who retires in December after 12-years as CFO

Daiichi Sankyo CFO Martin HesseDaiichi Sankyo has appointed Martin Hesse to be its new European chief financial officer (CFO) with effect from October, 1.

He will succeed Max Schöner, who retires on December, 31 after 12-years in the role, and joins Daiichi Sankyo Europe from Bayer, where he had served since 1984.

Hesse was most recently chief administration officer excellence at Bayer Healthcare, having previously held a series of senior roles that included VP of corporate auditing and CFO for Eastern Europe.

Daiichi Sankyo Europe's CEO Reinhard Bauer said: “We are excited that we could fill the position with such an expert.

“Daiichi Sankyo Europe is playing an increasingly important role within the group. It will be a major contributor in our effort to generate the bigger part of our group sales outside Japan. In his former positions, Hesse has proven his ability to achieve ambitious goals like these.” 

Commenting on the environment in which he starts at Daiichi, Hesse said securing the company's profitability and competitiveness in the light of drug pricing interventions will a major challenge.

“We'll have to come to terms with every mandatory discount. The key will be to skilfully combine cost reductions with strategic decisions.”

11th September 2012

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics